Yang Li Sells 1,118 Shares of Surrozen (NASDAQ:SRZN) Stock

Surrozen, Inc. (NASDAQ:SRZN) VP Yang Li sold 1,118 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $19.87, for a total value of $22,214.66. Following the completion of the sale, the vice president owned 16,091 shares of the company’s stock, valued at $319,728.17. The trade was a 6.50% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Surrozen Stock Performance

SRZN traded up $0.57 during midday trading on Tuesday, hitting $19.67. The stock had a trading volume of 78,574 shares, compared to its average volume of 85,990. Surrozen, Inc. has a 1 year low of $5.90 and a 1 year high of $24.94. The business has a fifty day moving average of $17.64 and a 200 day moving average of $13.39. The company has a market cap of $168.57 million, a P/E ratio of -0.88 and a beta of 0.58.

Surrozen (NASDAQ:SRZN) last announced its quarterly earnings data on Friday, November 7th. The company reported ($3.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($2.44). Surrozen had a negative return on equity of 4,055.04% and a negative net margin of 2,909.10%.The business had revenue of $0.98 million during the quarter. On average, equities research analysts anticipate that Surrozen, Inc. will post -8.49 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Citadel Advisors LLC lifted its position in shares of Surrozen by 32.8% in the 3rd quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock worth $179,000 after purchasing an additional 3,424 shares during the period. Geode Capital Management LLC raised its stake in Surrozen by 22.6% in the second quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock worth $277,000 after buying an additional 5,702 shares in the last quarter. Woodline Partners LP bought a new position in Surrozen in the third quarter worth about $621,000. Armistice Capital LLC purchased a new stake in Surrozen in the second quarter worth about $536,000. Finally, Schonfeld Strategic Advisors LLC bought a new stake in Surrozen during the 3rd quarter valued at approximately $889,000. 66.57% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently commented on SRZN. Lifesci Capital upgraded Surrozen to a “strong-buy” rating in a report on Thursday, November 13th. Wall Street Zen upgraded Surrozen to a “sell” rating in a research report on Friday, November 28th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Surrozen in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $32.00.

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.